Studies in syngeneic cancer models have shown that CD47 mAbs can effectively inhibit tumor growth and that efficacy is dependent on macrophages, dendritic cells, T cells, and their interactions [237,244,246,247]. This evidence concerns the gene CD47 and cancer.